In vivo hemin pre-conditioning targets the vascular and immunological compartments and restrains prostate tumor development

JAWORSKI, FELIPE M; GENTILINI LD; GUERON G; MEISS RP; ORTIZ EG; BERGUER PME; AHMED A; NAVONE N; RABINOVICH GA; COMPAGNO DG; LADERACH DJ AND VAZQUEZ ES

Praga

Congreso; 9th International Conference on Heme Oxygenase Prague 2016; 2016

Prostate cancer (PCa) is the second leading cause of cancer incidence in men worldwide. Most current therapies against this disease are designed to target the tumor cell. However, the surrounding microenvironment plays a leading role in enabling tumor growth and dissemination. ?Pre-conditioning? strategies constitute a relatively unexplored and exciting opportunity to shape tumor fate. In the presentstudy we used hemin, a well-known inducer of the homeostatic enzyme Heme Oxygenase-1 (HO-1), in an in vivo pre-conditioning model to assess PCa development. The stroma of fully immunocompetent mice (n=5) was conditioned by subcutaneous administration of hemin (200μl, 10μM) or its vehicle PBS prior to T-C1 tumor challenge. Hemin pre-conditioned animals showed a significant increase in tumor latency (57 days in hemin-treated mice vs. 47 days in control mice; P